Healthcare growth equity fund research profile
Somerset Indus Fund III is a healthcare-focused India private-equity vehicle investing growth capital in accessible care, diagnostics, pharmaceuticals and medtech. Current manager and independent transaction disclosures attribute Cyrix Healthcare, Printmann Offset and NU Hospitals to Fund III.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Somerset Indus Fund III uses a healthcare growth equity approach across Hospitals, diagnostics, pharmaceuticals.
Current evidence
Somerset Indus Capital Partners announced the final close of Fund III at approximately US$288 million in March 2026. Current manager materials and independent transaction reporting attribute Cyrix Healthcare, Printmann Offset and NU Hospitals to the vehicle, with NU Hospitals announced in December 2025.
Strategy
Healthcare growth equity
Sector focus
Hospitals, diagnostics, pharmaceuticals
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Somerset Indus Capital Partners announced the final close of Fund III at approximately US$288 million in March 2026. Current manager materials and independent transaction reporting attribute Cyrix Healthcare, Printmann Offset and NU Hospitals to the vehicle, with NU Hospitals announced in December 2025.
Investor questions
Somerset Indus Fund III is covered in Rupeia's private equity research universe. The current public record describes the strategy as Healthcare growth equity, with a sector focus of Hospitals, diagnostics, pharmaceuticals. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Somerset Indus Fund III in the reviewed public sources: Cyrix Healthcare, Printmann Offset, NU Hospitals. It does not represent a complete current portfolio unless the manager has published one.
Fund III reached a US$288 million close in 2026 and has publicly identified three investments. Earlier Somerset funds have disclosed exits and return signals, but Fund III realised outcomes and net performance are not yet publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Approximately US$288 million final close, announced March 2026.. Public terms or access information: Healthcare growth capital across India; vehicle fees, carry, ownership and reserve terms are not publicly disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Avinash Kenkare (Founding Partner); Mayur Sirdesai (Partner); Ramesh Kannan (Partner); Vaibhav Doshi (Partner). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund-level net returns, ownership percentages and India vehicle terms are not publicly disclosed; the public record currently identifies three Fund III investments..
2026-03-23: Somerset Indus Capital Partners announced the final close of Fund III at approximately US$288 million in March 2026. Current manager materials and independent transaction reporting attribute Cyrix Healthcare, Printmann Offset and NU Hospitals to the vehicle, with NU Hospitals announced in December 2025.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.